SYNH logo

Syneos Health, Inc. Class A Common Stock

SYNH

SYNH: Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

more

Show SYNH Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of SYNH by members of U.S. Congress

Politician Type Traded
Daniel Goldman House / D Sale $1,001 - $15,000 Jan. 31, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Jan. 23, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec. 06, 2022
Susie Lee House / D Sale $1,001 - $15,000 Nov. 30, 2022
Josh Gottheimer House / D Sale $1,001 - $15,000 Jan. 04, 2022
Susie Lee House / D Purchase $1,001 - $15,000 Sep. 24, 2021
Josh Gottheimer House / D Sale $1,001 - $15,000 Aug. 20, 2021
Gilbert Cisneros House / D Sale $1,001 - $15,000 Nov. 03, 2020
Gilbert Cisneros House / D Purchase $1,001 - $15,000 Aug. 15, 2019
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by SYNH's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $30,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Pharmacy Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Apr 20, 2023 Issue: Taxation/Internal Revenue Code Pharmacy Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Jan 20, 2023 Issue: Government Issues Taxation/Internal Revenue Code Pharmacy Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Oct 20, 2022 Issue: Government Issues Taxation/Internal Revenue Code Pharmacy Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Jul 20, 2022 Issue: Government Issues Taxation/Internal Revenue Code Pharmacy Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Pharmacy Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Jan 20, 2022 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code Medical/Disease Research/Clinical Labs
  • $30,000 Oct 20, 2021 Issue: Health Issues Medical/Disease Research/Clinical Labs Taxation/Internal Revenue Code Pharmacy
  • $30,000 Jul 20, 2021 Issue: Health Issues Taxation/Internal Revenue Code Pharmacy Medical/Disease Research/Clinical Labs
  • $30,000 Apr 20, 2021 Issue: Medical/Disease Research/Clinical Labs Health Issues Pharmacy
  • $30,000 Jan 21, 2021 Issue: Health Issues Pharmacy Medical/Disease Research/Clinical Labs
  • $30,000 Oct 20, 2020 Issue: Medical/Disease Research/Clinical Labs Pharmacy Health Issues
  • $30,000 Jul 20, 2020 Issue: Pharmacy Medical/Disease Research/Clinical Labs Health Issues
U.S. Patents

New patents grants

  • Patent Title: Intra-ocular lens for extended macular vision in patients with macular degeneration Aug. 08, 2023
  • Patent Title: Intraocular lens system Apr. 25, 2023
  • Patent Title: Intraocular lens for extended macular vision in patients with macular degeneration Oct. 19, 2021
  • Patent Title: Intraocular lens system Mar. 30, 2021
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of SYNH in WallStreetBets Daily Discussion

SYNH News

Recent insights relating to SYNH

CNBC Recommendations

Recent picks made for SYNH stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SYNH

Corporate Flights

Flights by private jets registered to SYNH